Evgeny Gotovkin

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

Jianming Xu, Ken Kato, Eric Raymond et al. · The Lancet Oncology · 2023 · 291 citations

Medicine, Oncology, Pharmacology +12

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

David Cunningham, Niall C. Tebbutt, André M. Murad et al. · Journal of Clinical Oncology · 2015 · 143 citations

Medicine, Oncology, Pharmacology +12

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

Quality of Life in the Trastuzumab for Gastric Cancer Trial

Taroh Satoh, Yung‐Jue Bang, Evgeny Gotovkin et al. · The Oncologist · 2014 · 57 citations · Full text

Medicine, Oncology, Pharmacology +14

FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Salah‐Eddin Al‐Batran, Martin Schüler, Zanete Zvirbule et al. · Journal of Clinical Oncology · 2016 · 46 citations

Medicine, Oncology, Pharmacology +17